Supreme Court, Roundup, CRISPR, CDC office: Morning Rounds

Democrats Question if Trump Used Eli Lilly’s Obesity Drug

Following a report by STAT reporter Lizzy Lawrence, Democratic lawmakers are raising concerns about a 79-year-old patient who was granted access to Eli Lilly’s experimental obesity drug, retatrutide, in April. There are speculations that the patient in question could potentially be President Trump, although this has not been confirmed.

Senator Maggie Hassan and Representative Ted Lieu are seeking answers from the Trump administration regarding the identity of the patient and potential side effects of the drug. The revelation that a patient received retatrutide through the FDA’s compassionate use program has sparked further inquiries.

Supreme Court Ruling on Roundup Weedkiller

In a recent ruling, the Supreme Court decided that the manufacturer of Roundup weedkiller cannot be held liable for failure-to-warn lawsuits in state courts. This decision is based on federal regulations that have not found a definitive link between Roundup and cancer, thus no warning label is required.

The ruling is expected to dismiss numerous lawsuits against Bayer, the maker of Roundup, alleging failure to warn about potential cancer risks. Despite the company’s denial of these claims, Bayer has set aside funds for settlements and removed glyphosate from Roundup in the U.S.

Advancements in Genome Editing and Ethical Concerns

New research published in Nature has shed light on the potential of genome-editing tools in early embryos. The study suggests that next-generation CRISPR technology is more precise and less destructive, opening up possibilities for editing genes in embryos before implantation.

However, the ethical implications of using such tools to “design” babies remain a topic of debate. While the technology shows promise, there are still technical challenges and ethical considerations that need to be addressed before widespread implementation.

Challenges with Medetomidine Withdrawal in Jails

A potent tranquilizer, medetomidine, is emerging as a new challenge in the illicit opioid supply chain, particularly in jails where prisoners may experience withdrawal symptoms. The drug’s withdrawal can be excruciating and complex, requiring specialized treatment that may not be readily available in correctional facilities.

Jails across the country are grappling with how to manage medetomidine withdrawal, as the drug’s detection and treatment present unique challenges. The CDC has reported the prevalence of medetomidine in drug samples, signaling a growing concern for public health officials.

Potential Political Control Over CDC Information

A proposal to establish a separate science office above the CDC could give political appointees more control over the agency’s research and information dissemination. While the plan is not finalized due to funding constraints, it reflects the Trump administration’s efforts to influence the CDC’s messaging.

If implemented, the new office could impact the CDC’s scientific publications and briefings, raising concerns about political interference in public health matters. The move aligns with previous attempts to assert control over the agency’s communications.

Updates to Vaccine Committee Charter

A revised charter for the CDC’s vaccine advisory panel has sparked controversy by reshaping the committee’s role in vaccine recommendations and assessment. The new document emphasizes a diverse range of expertise on the panel, potentially diluting the focus on vaccination policy.

The changes to the committee’s composition have raised concerns about its effectiveness in providing informed guidance on vaccine use. Public health experts warn that the reconfigured panel may undermine its credibility and effectiveness in addressing immunization challenges.

Additional Readings

• White House and RFK Jr. attempt to influence House races by urging third-party candidates to withdraw – Washington Post
• Legislation proposed to regulate the 340B drug discount program – STAT
• Concerns raised about misleading studies produced by medical students using research tools – Science
• Highlights from BIO 2026 conference discussing industry challenges and advancements in AI – STAT
• Transgender individuals at risk of missing out on cervical cancer screenings – CIDRAP